BACKGROUND: In the Post-Exposure Prophylaxis of Infants (PEPI)-Malawi trial, most women received single-dose nevirapine (NVP) at delivery, and infants in the extended study arms received single-dose NVP along with 1 week of daily zidovudine (ZDV), followed by either extended daily NVP or extended daily NVP and ZDV up to 14 weeks of age. Although extended NVP prophylaxis reduces the risk of postnatal HIV transmission, it may increase the risk of NVP resistance among infants who are HIV-infected despite prophylaxis. METHODS: We analyzed 88 infants in the PEPI-Malawi trial who were HIV-infected in utero and who received prophylaxis for a median of 6 weeks prior to HIV diagnosis. HIV genotyping was performed using the ViroSeq HIV Genotyping System. RESULTS: At 14 weeks of age, the proportion of infants with NVP resistance was lower in the extended NVP and ZDV arm than in the extended NVP arm (28/45, 62.2% vs. 37/43, 86.0%; P = 0.015). None of the infants had ZDV resistance. Addition of extended ZDV to extended NVP was associated with reduced risk of NVP resistance at 14 weeks if prophylaxis was stopped by 6 weeks (54.5 vs. 85.7%, P = 0.007) but not if prophylaxis was continued beyond 6 weeks (83.3 vs. 87.5%, P = 1.00). CONCLUSION: Addition of extended ZDV to extended NVP prophylaxis significantly reduced the risk of NVP resistance at 14 weeks in infants who were HIV-infected in utero, provided that HIV infection was diagnosed and the prophylaxis was stopped by 6 weeks of age.
RCT Entities:
BACKGROUND: In the Post-Exposure Prophylaxis of Infants (PEPI)-Malawi trial, most women received single-dose nevirapine (NVP) at delivery, and infants in the extended study arms received single-dose NVP along with 1 week of daily zidovudine (ZDV), followed by either extended daily NVP or extended daily NVP and ZDV up to 14 weeks of age. Although extended NVP prophylaxis reduces the risk of postnatal HIV transmission, it may increase the risk of NVP resistance among infants who are HIV-infected despite prophylaxis. METHODS: We analyzed 88 infants in the PEPI-Malawi trial who were HIV-infected in utero and who received prophylaxis for a median of 6 weeks prior to HIV diagnosis. HIV genotyping was performed using the ViroSeq HIV Genotyping System. RESULTS: At 14 weeks of age, the proportion of infants with NVP resistance was lower in the extended NVP and ZDV arm than in the extended NVP arm (28/45, 62.2% vs. 37/43, 86.0%; P = 0.015). None of the infants had ZDV resistance. Addition of extended ZDV to extended NVP was associated with reduced risk of NVP resistance at 14 weeks if prophylaxis was stopped by 6 weeks (54.5 vs. 85.7%, P = 0.007) but not if prophylaxis was continued beyond 6 weeks (83.3 vs. 87.5%, P = 1.00). CONCLUSION: Addition of extended ZDV to extended NVP prophylaxis significantly reduced the risk of NVP resistance at 14 weeks in infants who were HIV-infected in utero, provided that HIV infection was diagnosed and the prophylaxis was stopped by 6 weeks of age.
Authors: W T Shearer; T C Quinn; P LaRussa; J F Lew; L Mofenson; S Almy; K Rich; E Handelsman; C Diaz; M Pagano; V Smeriglio; L A Kalish Journal: N Engl J Med Date: 1997-05-08 Impact factor: 91.245
Authors: Susan H Eshleman; Laura A Guay; Anthony Mwatha; Elizabeth R Brown; Shawn P Cunningham; Philippa Musoke; Francis Mmiro; J Brooks Jackson Journal: J Acquir Immune Defic Syndr Date: 2004-02-01 Impact factor: 3.731
Authors: Susan H Eshleman; Donald R Hoover; Sarah E Hudelson; Shu Chen; Susan A Fiscus; Estelle Piwowar-Manning; J Brooks Jackson; Newton I Kumwenda; Taha E Taha Journal: J Infect Dis Date: 2006-01-11 Impact factor: 5.226
Authors: Jessica D Church; Saad B Omer; Laura A Guay; Wei Huang; Jessica Lidstrom; Philippa Musoke; Francis Mmiro; J Brooks Jackson; Susan H Eshleman Journal: J Infect Dis Date: 2008-10-01 Impact factor: 5.226
Authors: Newton I Kumwenda; Donald R Hoover; Lynne M Mofenson; Michael C Thigpen; George Kafulafula; Qing Li; Linda Mipando; Kondwani Nkanaunena; Tsedal Mebrahtu; Marc Bulterys; Mary Glenn Fowler; Taha E Taha Journal: N Engl J Med Date: 2008-06-04 Impact factor: 91.245
Authors: Avy Violari; Mark F Cotton; Diana M Gibb; Abdel G Babiker; Jan Steyn; Shabir A Madhi; Patrick Jean-Philippe; James A McIntyre Journal: N Engl J Med Date: 2008-11-20 Impact factor: 91.245
Authors: Jessica D Church; Anthony Mwatha; Danstan Bagenda; Saad B Omer; Deborah Donnell; Philippa Musoke; Clemensia Nakabiito; Chineta Eure; Paul Bakaki; Flavia Matovu; Michael C Thigpen; Laura A Guay; Michelle McConnell; Mary Glenn Fowler; J Brooks Jackson; Susan H Eshleman Journal: AIDS Res Hum Retroviruses Date: 2009-07 Impact factor: 2.205
Authors: Jessica Fogel; Donald R Hoover; Jin Sun; Lynne M Mofenson; Mary G Fowler; Allan W Taylor; Newton Kumwenda; Taha E Taha; Susan H Eshleman Journal: AIDS Date: 2011-04-24 Impact factor: 4.177
Authors: Jessica Fogel; Qing Li; Taha E Taha; Donald R Hoover; Newton I Kumwenda; Lynne M Mofenson; Johnstone J Kumwenda; Mary Glenn Fowler; Michael C Thigpen; Susan H Eshleman Journal: Clin Infect Dis Date: 2011-04-15 Impact factor: 9.079
Authors: Silvia Bertagnolio; Martina Penazzato; Michael R Jordan; Deborah Persaud; Lynne M Mofenson; Diane E Bennett Journal: Clin Infect Dis Date: 2012-05 Impact factor: 9.079
Authors: Jessica M Fogel; Anthony Mwatha; Paul Richardson; Elizabeth R Brown; Tsungai Chipato; Michel Alexandre; Dhayendre Moodley; Ali Elbireer; Mark Mirochnick; Kathleen George; Lynne M Mofenson; Sheryl Zwerski; Hoosen M Coovadia; Susan H Eshleman Journal: Pediatr Infect Dis J Date: 2013-04 Impact factor: 2.129